Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma.
- Authors: MarÃn, GH; Mansilla, E; Mezzaroba, N; Zorzet, S; Núñez, L; Larsen, G; Tau, JM; Maceira, A; Spretz, R; Mertz, C; Ingrao, S; Tripodo, C; Tedesco, F; Macor, P.
- Publication year: 2010
- Type: Articolo in rivista (Articolo in rivista)
- OA Link: http://hdl.handle.net/10447/57803
Abstract
The aim of this study was to determine if Rituximab coated Biodegradable Nanoparticles (BNPs) loaded with Chlorambucil and Hydroxychloroquine could induce apoptosis of B-Chronic Lymphocytic Leukemia (B-CLL), MEC-1 and BJAB cells in vitro and evaluate their toxic and therapeutic effects on a Human/Mouse Model of Burkitt Lymphoma at an exploratory, proof of concept scale. We found that Rituximab-Chlorambucil-Hydroxychloroquine BNPs induce a decrease in cell viability of malignant B cells in a dose-dependent manner. The mediated cytotoxicity resulted from apoptosis, and was confirmed by monitoring the B-CLL cells after Annexin V/propidium iodide staining. Additional data revealed that these BNPs were non toxic for healthy animals, and had prolonged survival in this mice model of human lymphoma.